Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ROBAXIN vs CHLORZOXAZONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Centrally acting muscle relaxant; depresses polysynaptic reflexes at spinal cord and supraspinal levels, possibly via glycine receptor agonism and GABAergic modulation.
Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.
Relief of discomfort associated with acute, painful musculoskeletal conditions,Adjunct to rest, physical therapy, and other measures
Adjunct for relief of acute painful musculoskeletal conditions associated with muscle spasm
1500 mg orally 4 times daily, or 750 mg orally every 4 hours as needed. Maximum 6 g/day. For IV use: 1 g (10 m L) as a single intravenous injection or infusion.
250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.
1-2 hours in adults; clinically, multiple daily dosing required to maintain effect.
Terminal elimination half-life approximately 1–2 hours; clinically relevant for muscle relaxant effect duration.
Hepatic metabolism via CYP450 enzymes (primarily CYP1A2, CYP3A4); active metabolite (methocarbamol).
Hepatic, primarily via CYP2E1, also CYP1A2 and CYP3A4
Renal excretion of metabolites accounts for 99% of elimination; <1% excreted as unchanged drug in urine.
Primarily hepatic metabolism followed by renal excretion of metabolites; <1% excreted unchanged in urine; minor biliary/fecal elimination.
50% bound to albumin.
Approximately 90–95% bound, primarily to albumin.
0.5-1.0 L/kg; indicates distribution into total body water.
0.46–0.64 L/kg; indicates distribution into total body water.
Oral: 80-100% (extensive absorption, first-pass metabolism minimal).
Oral: nearly complete; rapidly absorbed with extensive first-pass metabolism; systemic bioavailability approximately 30–50% due to first-pass effect.
In severe renal impairment (Cr Cl <30 m L/min), reduce dose by 50% and monitor for CNS effects. Avoid use in anuria.
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation of active metabolite.
Contraindicated in severe hepatic impairment (Child-Pugh class C). Use with caution in mild to moderate impairment; reduce dose by 50% and monitor for sedation.
Contraindicated in hepatic impairment; avoid use in Child-Pugh class B or C due to risk of hepatotoxicity.
Not recommended for children under 12 years. For ages ≥12 years: same as adult dosing.
Not established; safety and efficacy not studied in pediatric patients.
Initiate at reduced dose (e.g., 750 mg 4 times daily) due to increased sensitivity and risk of sedation; titrate cautiously and monitor renal function.
Initiate at lower end of dosing range (250 mg 3-4 times daily); monitor for CNS effects (dizziness, drowsiness) and liver function.
None
None
May cause drowsiness or dizziness; caution with driving or operating machinery,Risk of serotonin syndrome with concomitant serotonergic drugs,Hepatic impairment; monitor liver function,Renal impairment; caution in severe cases,Use with caution in elderly and debilitated patients
May cause drowsiness, dizziness, or impaired coordination. Caution in patients with hepatic impairment. Discontinue if hypersensitivity reactions occur. Avoid concurrent use with alcohol or other CNS depressants.
Hypersensitivity to methocarbamol or any component,Myasthenia gravis,Known hypersensitivity to cyclobenzaprine or related compounds (if formulation includes)
Hypersensitivity to chlorzoxazone or any component of the formulation; impaired hepatic function
No significant food interactions. However, take with food if gastrointestinal upset occurs. Avoid alcohol.
No significant food interactions. Take with or without food. Grapefruit juice may increase drug levels; avoid large quantities.
No adequate well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Risk cannot be ruled out. Use only if clearly needed. First trimester: potential risk unknown. Second and third trimesters: may be associated with neonatal respiratory depression if used near delivery.
Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if clearly needed and after weighing risks vs. benefits. Avoid during first trimester unless necessary.
Methocarbamol is excreted in human milk in small amounts. The M/P ratio is unknown. Caution should be exercised when administered to a nursing woman. Monitor infant for sedation.
Not recommended during breastfeeding due to potential for sedation in the infant. No M/P ratio data available.
No specific dosing adjustments are recommended due to lack of pharmacokinetic data in pregnancy. Use lowest effective dose for shortest duration.
No dosage adjustment specific to pregnancy is required based on pharmacokinetic data; however, clinical response should be monitored.
ROBAXIN (methocarbamol) is a centrally acting muscle relaxant indicated for acute musculoskeletal pain. Onset of action is within 30 minutes; peak effect at 2 hours. Avoid in patients with myasthenia gravis. Renal impairment requires dose adjustment. Can cause sedation; avoid concurrent CNS depressants. IV formulation may cause hemolysis if extravasation occurs.
Chlorzoxazone is a centrally acting muscle relaxant used for acute musculoskeletal pain. Onset of action is within 1 hour; peak effect at 1-2 hours. Monitor for hepatotoxicity, especially with prolonged use or high doses. Can cause drowsiness and impair motor skills; avoid concurrent use with alcohol or other CNS depressants. Tablets may be crushed for patients with swallowing difficulties.
Drowsiness and dizziness are common; do not drive or operate machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids).,Take exactly as prescribed; do not increase dose or frequency.,May cause urine discoloration (brown, black, or blue-green); this is harmless.,Notify your doctor if you experience rash, itching, or difficulty breathing.,Do not stop abruptly; taper dose if discontinuing after prolonged use.
Take exactly as prescribed; do not increase dose or frequency.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Report signs of liver problems: dark urine, yellowing of eyes/skin, persistent nausea, abdominal pain.,Do not suddenly stop taking if used long-term; taper under medical supervision to avoid withdrawal.
No interactions on record
"Lumacaftor is a strong inducer of cytochrome P450 (CYP) 3A4 and other drug-metabolizing enzymes, including CYP2E1. Chlorzoxazone is primarily metabolized by CYP2E1 to its inactive metabolite. Concomitant use increases CYP2E1 activity, leading to accelerated chlorzoxazone clearance and reduced systemic exposure, potentially diminishing its therapeutic effect as a muscle relaxant."
"Chlorzoxazone, a centrally acting muscle relaxant, inhibits the metabolism of diltiazem, a calcium channel blocker, via competitive inhibition of CYP3A4. This leads to increased plasma concentrations of diltiazem, potentially causing enhanced negative chronotropic and vasodilatory effects, resulting in bradycardia, hypotension, or atrioventricular block. Patients may experience dizziness, syncope, or exacerbate heart failure symptoms."
"Butalbital, a barbiturate, induces hepatic cytochrome P450 enzymes (particularly CYP2E1), accelerating the metabolism of chlorzoxazone, a centrally acting muscle relaxant primarily metabolized by CYP2E1. This results in reduced plasma concentrations of chlorzoxazone, leading to diminished therapeutic efficacy and potential loss of symptom control. Clinically, patients may experience inadequate muscle relaxation, requiring dose adjustments or alternative therapy."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ROBAXIN vs CHLORZOXAZONE, answered by our medical review team.
ROBAXIN is a Skeletal Muscle Relaxant that works by Centrally acting muscle relaxant; depresses polysynaptic reflexes at spinal cord and supraspinal levels, possibly via glycine receptor agonism and GABAergic modulation.. CHLORZOXAZONE is a Skeletal Muscle Relaxant that works by Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ROBAXIN and CHLORZOXAZONE depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ROBAXIN is: 1500 mg orally 4 times daily, or 750 mg orally every 4 hours as needed. Maximum 6 g/day. For IV use: 1 g (10 m L) as a single intravenous injection or infusion.. The standard adult dose of CHLORZOXAZONE is: 250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ROBAXIN and CHLORZOXAZONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ROBAXIN is classified as Category C. No adequate well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Risk cannot be ruled out. Use only if clearly needed. First trimester: p. CHLORZOXAZONE is classified as Category C. Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if cl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.